Is expectant management of early-onset severe preeclampsia worthwhile in low-resource settings?
OBJECTIVE
To evaluate the maternal and perinatal outcome following expectant management of early-onset severe preeclampsia (PE) at a tertiary hospital in Mansoura, Egypt.


METHODS
This prospective, observational study included 211 patients with severe PE, occurring between 24 and 34 weeks of gestation. They were classified according to gestational age on admission into three groups. Group 1 included 61 patients with gestational ages between 24 and 28 weeks. Group 2 (28 to <32 weeks) included 66 patients and group 3 (32-34 weeks) included 84 patients. Outcome measures included prolongation of gestation, and maternal and perinatal complications.


RESULTS
The median overall prolongation of gestation was 12 +/- 6 days. The rate of neonatal survival significantly increased (P < 0.001) from 12/61 (19.7%) in group 1 to 30/66 (45.5%) in group 2 and 67/84 (79.8%) in group 3. There were no maternal mortalities; however, 43 (20.4%) women developed significant morbidities. HELLP syndrome, renal impairment and placental abruption were the main complications.


CONCLUSIONS
In low-resource settings, expectant management of early-onset severe PE is associated with relatively higher rates of perinatal mortality and maternal morbidity and should be limited to gestational ages between 28 and 34 weeks of gestation.
Abdel-Hady
El-Said
el-S
Department of Obstetrics and Gynecology, Mansoura University, Mansoura, Egypt.
Fawzy
Muhammad
M
El-Negeri
Mohamed
M
Nezar
Mohamed
M
Ragab
Ahmed
A
Helal
Adel Saad
AS
D000293:Adolescent; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D004534:Egypt; D005260:Female; D005313:Fetal Death; D005323:Fetal Monitoring / Q000379:methods; D005865:Gestational Age; D005938:Glucocorticoids / Q000008:administration & dosage; D006784:Hospitals, Teaching; D006801:Humans; D007231:Infant, Newborn; D007741:Labetalol / Q000008:administration & dosage; D007902:Length of Stay; D008750:Methyldopa / Q000008:administration & dosage; D011225:Pre-Eclampsia / Q000517:prevention & control / Q000628:therapy; D011247:Pregnancy; D011256:Pregnancy Outcome; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D011446:Prospective Studies; D012307:Risk Factors; D055815:Young Adult
D000959:Antihypertensive Agents; D005938:Glucocorticoids; D008750:Methyldopa; D007741:Labetalol